secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001193125-24-284671
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics raises $30M via registered direct offering of pre-funded warrants to Lynx1 Capital
--------------------------------------------------------------------------------

- Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.
- Purchaser is Lynx1 Capital Management LP and an affiliated fund, an existing shareholder.
- Net proceeds ~$29.8M for general corporate purposes; closing expected Dec 27, 2024.
- Cash runway extended into Q1 2027 based on net proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524284671/0001193125-24-284671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524284671/d861236d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-284671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer